DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $12.3333.

Several analysts have recently weighed in on the company. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in shares of DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after acquiring an additional 154,701 shares during the period. Goldman Sachs Group Inc. boosted its stake in DiaMedica Therapeutics by 76.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock worth $462,000 after purchasing an additional 52,854 shares during the period. Jane Street Group LLC grew its position in DiaMedica Therapeutics by 138.5% during the 1st quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock worth $382,000 after purchasing an additional 58,457 shares during the last quarter. Geode Capital Management LLC grew its position in DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in DiaMedica Therapeutics in the second quarter valued at $29,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Price Performance

Shares of DMAC opened at $6.79 on Friday. DiaMedica Therapeutics has a 1-year low of $3.19 and a 1-year high of $10.42. The stock has a market cap of $353.62 million, a PE ratio of -9.56 and a beta of 1.09. The firm has a fifty day moving average price of $7.90 and a 200 day moving average price of $7.66.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.